170 related articles for article (PubMed ID: 26179864)
1. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
Peñalver FJ; Delgado J; Loscertales J; Sastre JL; Peña A; Olave MT; Osorio S; de la Fuente A; Salar A; Grande C; Pérez Ceballos E; Debén G; Echeveste A; Casado F; de la Rubia J; Lahuerta JJ; Mateos MV
Eur J Haematol; 2016 May; 96(5):532-40. PubMed ID: 26179864
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon.
Musto P; Fraticelli VL; Mansueto G; Madonna E; Nozza A; Andriani A; Mussetti A; Ballanti S; Bongarzoni V; Baraldi A; Patriarca F; Vincelli D; Falcone A; Derudas D; Califano C; Zambello R; Mele G; Fragasso A; Baldini L; Storti S
Leuk Lymphoma; 2015 May; 56(5):1510-3. PubMed ID: 25651428
[No Abstract] [Full Text] [Related]
3. Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.
Cheson BD; Brugger W; Damaj G; Dreyling M; Kahl B; Kimby E; Ogura M; Weidmann E; Wendtner CM; Zinzani PL
Leuk Lymphoma; 2016; 57(4):766-82. PubMed ID: 26592922
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
Howell M; Gibb A; Radford J; Linton K
Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
[No Abstract] [Full Text] [Related]
5. United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma.
Pratt G; Bowcock S; Lai M; Bell S; Bird J; D'Sa S; Cavenagh J; Cook G; Morgan G; Owen R; Snowden JA; Yong K; Davies F;
Int J Lab Hematol; 2014 Feb; 36(1):20-8. PubMed ID: 23615178
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine therapy associated resolution of anemia and splenomegaly in myelofibrosis.
Tefferi A; Cerquozzi S; Liaw J
Am J Hematol; 2016 Feb; 91(2):E6-7. PubMed ID: 26587685
[No Abstract] [Full Text] [Related]
7. High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients.
Prediletto I; Farag SA; Bacher U; Jeker B; Mansouri Taleghani B; Brégy R; Zander T; Betticher D; Egger T; Novak U; Pabst T
Bone Marrow Transplant; 2019 Dec; 54(12):1923-1925. PubMed ID: 30890768
[No Abstract] [Full Text] [Related]
8. Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.
Palumbo A; Offidani M; Patriarca F; Petrucci MT; Cavo M
Leuk Lymphoma; 2015 Mar; 56(3):559-67. PubMed ID: 24884319
[TBL] [Abstract][Full Text] [Related]
9. Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies.
Penne M; Sarraf Yazdy M; Nair KS; Cheson BD
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):637-644. PubMed ID: 28797620
[TBL] [Abstract][Full Text] [Related]
10. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
11. The role of bendamustine in the management of plasma cell myeloma.
Gertz MA
Leuk Lymphoma; 2015 May; 56(5):1195-6. PubMed ID: 25347428
[No Abstract] [Full Text] [Related]
12. Bendamustine associated immune suppression and infections during therapy of hematological malignancies.
Gafter-Gvili A; Polliack A
Leuk Lymphoma; 2016; 57(3):512-9. PubMed ID: 26696321
[TBL] [Abstract][Full Text] [Related]
13. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859
[No Abstract] [Full Text] [Related]
14. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
Kumar SK; Krishnan A; LaPlant B; Laumann K; Roy V; Zimmerman T; Gertz MA; Buadi FK; Stockerl Goldstein K; Birgin A; Fiala M; Duarte L; Maharaj M; Levy J; Vij R
Am J Hematol; 2015 Dec; 90(12):1106-10. PubMed ID: 26331432
[TBL] [Abstract][Full Text] [Related]
16. Acquired Gitelman Syndrome Secondary to Bendamustine Use.
Rogers A; Gandhi P; Bautista J; Tang J
R I Med J (2013); 2018 Nov; 101(9):36-38. PubMed ID: 30384518
[No Abstract] [Full Text] [Related]
17. Bendamustine: role and evidence in lymphoma therapy, an overview.
Derenzini E; Zinzani PL; Cheson BD
Leuk Lymphoma; 2014 Jul; 55(7):1471-8. PubMed ID: 24180334
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
19. Bendamustine-Induced Nephrogenic Diabetes Insipidus in a Patient With AL Amyloidosis.
Uwumugambi NA; Sanchorawala V; Shelton AC; Stern L; Gordon CE
Am J Kidney Dis; 2017 Feb; 69(2):317-319. PubMed ID: 27780577
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine in the treatment of multiple myeloma: results and future perspectives.
Pönisch W; Niederwieser D
Semin Oncol; 2002 Aug; 29(4 Suppl 13):23-6. PubMed ID: 12170429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
